Galapagos N.V. (GLPG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galapagos N.V. (GLPG) has a cash flow conversion efficiency ratio of -0.024x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-78.61 Million ≈ $-91.91 Million USD) by net assets (€3.25 Billion ≈ $3.80 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Galapagos N.V. (GLPG) defensive interval to measure how many days the company can operate on defensive assets alone.
Galapagos N.V. - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Galapagos N.V.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Galapagos N.V. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galapagos N.V. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taiji Computer Corp Ltd
SHE:002368
|
0.046x |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
0.056x |
|
Realia
MC:RLIA
|
0.038x |
|
Kepco Plant S&
KO:051600
|
0.008x |
|
Renew Energy Global PLC
NASDAQ:RNW
|
-0.012x |
|
China Railway Construction Corporation Limited
F:4FF
|
0.045x |
|
Jiangsu Jujie Microfiber Technology
SHE:300819
|
0.079x |
|
Friedrich Vorwerk Group SE
F:VH2
|
0.147x |
Annual Cash Flow Conversion Efficiency for Galapagos N.V. (2004–2025)
The table below shows the annual cash flow conversion efficiency of Galapagos N.V. from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see Galapagos N.V. market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €3.24 Billion ≈ $3.78 Billion |
€-197.01 Million ≈ $-230.32 Million |
-0.061x | +44.89% |
| 2024-12-31 | €2.90 Billion ≈ $3.39 Billion |
€-320.03 Million ≈ $-374.14 Million |
-0.110x | +23.93% |
| 2023-12-31 | €2.80 Billion ≈ $3.27 Billion |
€-405.97 Million ≈ $-474.62 Million |
-0.145x | +26.71% |
| 2022-12-31 | €2.53 Billion ≈ $2.95 Billion |
€-500.54 Million ≈ $-585.19 Million |
-0.198x | -3.96% |
| 2021-12-31 | €2.64 Billion ≈ $3.09 Billion |
€-503.83 Million ≈ $-589.03 Million |
-0.191x | -19.10% |
| 2020-12-31 | €2.67 Billion ≈ $3.12 Billion |
€-427.34 Million ≈ $-499.60 Million |
-0.160x | -114.34% |
| 2019-12-31 | €2.88 Billion ≈ $3.36 Billion |
€3.21 Billion ≈ $3.75 Billion |
1.116x | +1050.99% |
| 2018-12-31 | €1.21 Billion ≈ $1.42 Billion |
€-142.47 Million ≈ $-166.56 Million |
-0.117x | +19.24% |
| 2017-12-31 | €1.01 Billion ≈ $1.18 Billion |
€-147.03 Million ≈ $-171.89 Million |
-0.145x | -146.04% |
| 2016-12-31 | €758.70 Million ≈ $887.00 Million |
€239.40 Million ≈ $279.89 Million |
0.316x | +200.51% |
| 2015-12-31 | €365.00 Million ≈ $426.72 Million |
€-114.59 Million ≈ $-133.97 Million |
-0.314x | +14.35% |
| 2014-12-31 | €206.13 Million ≈ $240.99 Million |
€-75.56 Million ≈ $-88.33 Million |
-0.367x | -11835.82% |
| 2013-12-31 | €167.14 Million ≈ $195.40 Million |
€522.00K ≈ $610.27K |
0.003x | -99.42% |
| 2012-12-31 | €118.45 Million ≈ $138.48 Million |
€64.10 Million ≈ $74.94 Million |
0.541x | +634.28% |
| 2011-12-31 | €118.38 Million ≈ $138.39 Million |
€-11.99 Million ≈ $-14.02 Million |
-0.101x | +19.01% |
| 2010-12-31 | €148.51 Million ≈ $173.62 Million |
€-18.57 Million ≈ $-21.71 Million |
-0.125x | -316.03% |
| 2009-12-31 | €108.88 Million ≈ $127.29 Million |
€6.30 Million ≈ $7.37 Million |
0.058x | +159.47% |
| 2008-12-31 | €84.32 Million ≈ $98.58 Million |
€-8.21 Million ≈ $-9.60 Million |
-0.097x | -2687.95% |
| 2007-12-31 | €98.63 Million ≈ $115.30 Million |
€371.00K ≈ $433.74K |
0.004x | +104.43% |
| 2006-12-31 | €109.54 Million ≈ $128.07 Million |
€-9.31 Million ≈ $-10.88 Million |
-0.085x | -33.68% |
| 2005-12-31 | €61.14 Million ≈ $71.47 Million |
€-3.89 Million ≈ $-4.54 Million |
-0.064x | +75.68% |
| 2004-12-31 | €10.37 Million ≈ $12.12 Million |
€-2.71 Million ≈ $-3.17 Million |
-0.261x | -- |
About Galapagos N.V.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory no… Read more